August 3, 2020 -- Eli Lilly has begun a phase III trial of its lead COVID-19 antibody treatment candidate, Ly-CoV555.
The Blaze-2 trial will investigate whether Ly-CoV555 can prevent COVID-19 among residents and staff at long-term care facilities, which have been uniquely impacted by viral outbreaks.
The candidate is a potent, neutralizing immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the novel coronavirus's spike protein, the company noted. Lilly is also investigating Ly-CoV555 in a randomized, double-blind phase I trial that is currently being conducted by medical centers in the U.S.
The Blaze-2 trial will evaluate the safety and efficacy of Ly-CoV555 for preventing infection and test whether a single dose can reduce infection rates and COVID-19 complications. It will enroll up to 2,400 participants who are at a high risk of novel coronavirus exposure due to living or working in a facility with a recently diagnosed COVID-19 case.
The trial is being conducted as a partnership among Lilly, the U.S. National Institute of Allergy and Infectious Diseases, the COVID-19 Prevention Network, and several long-term care facilities in the U.S. To meet the challenges of conducting a clinical trial in a long-term care facility, Lilly has created custom mobile research units that included retrofitting recreational vehicles with mobile labs and trailer trucks to deliver clinical trial supplies.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
